A word from
Already, 2023 is shaping up to be a terrific year for the adMare team.
In January, we celebrated the graduation of the first cohort of our accelerator pilot program. Entrepreneurs from Cura Therapeutics, Modelis, Molecular Forecaster, Targa Biomedical, Trepso Therapeutics, and Valence Discovery shared how adMare had helped them grow their companies and achieve important milestones. Building on this success, we launched the adMare National Tx Accelerator, inviting early-stage biotechnology and therapeutics ventures from across Canada to apply to our program. Participants gain access to our team's scientific and commercialization expertise, funding, network, lab space, and training to accelerate the growth and scale up of their business. We are proud to expand our reach and support of life sciences companies across Canada and in Ontario through our partnership with MaRS Discovery District in Toronto.
Our portfolio companies are doing well, with some reaching important milestones recently. At the BIOTECanada Whistler Investor Summit earlier this month, we hosted the Emerging Companies Forum and heard about exciting projects from new companies: Overture Therapeutics, FiND Therapeutics, Immugenia, and Evolved Therapeutics.
In the past few weeks, we presented two highly interesting webinars. The first featured Dr. Melissa Moore, Chief Scientist Officer Emeritus at Moderna, who shared her team's experience in accelerating the development of the mRNA technology to find a solution for the pandemic. The second webinar showcased Dr. Jeremy Duffield's presentation of Prime Medicine's fascinating gene editing technology.
At adMare, we believe in the power of partnerships to build a stronger life science industry. We're excited to announce our new partnership with PRiME Next-Generation Precision Medicine in Toronto. Together we will identify disruptive academic research and translate it into life-changing therapeutics. We'd also like to congratulate our partner in talent development, CASTL, for their exciting news of new facilities in Prince Edward Island, British Columbia, and Montreal, which will extend the development of talent in biomanufacturing across Canada.
We're proud to be involved in the Government of Canada's collaborative initiative with new research hubs, which encourages academic and industry actors to partner and accelerate Canada's vaccine and therapeutics production. adMare is contributing to these five hubs through our unique talent development programs and expertise to advance the investment readiness of new emerging technologies.
Finally, we're excited to announce the launch of the BioInnovation Scientist (BIS) Program: Foundations by the adMare Academy. This program is designed to help young scientists build their professional skills and succeed in the Canadian life sciences industry. This new version of the program brings trainees together as a cohort, enhancing the participant experience and facilitating peer network building.
With all these developments and projects underway, we're looking forward to a tremendous year for the life science industry, with new companies and innovative therapeutics for the patients.
Gordon C. McCauley
President and CEO, adMare BioInnovations
adMare BioInnovations and PRiME Next-Generation Precision Medicine collaborate to translate academic research into life-changing therapeutics
adMare and PRiME, an Institutional Strategic Initiative at the University of Toronto, announced their new partnership to support the building of new Canadian life science companies and therapeutic products through the advancement of precision medicine research and commercialization.
Thryv Therapeutics Inc., an adMare portfolio company, announced completion of initial phase 1 clinical study and beginning of proof of efficacy study in Long QT Syndrome
"We are excited by the results from our initial phase 1 clinical study with LQT-1213, including excellent safety, tolerability, and a predictable pharmacokinetic profile with dosing up to seven days. We now will take the next steps to develop LQT-1213 for adults and children with Congenital LQTS - a patient population without an approved therapy," said Philip Sager, MD, FAHA, FHRS, Co-founder and Chief Medical Officer of Thryv Therapeutics.
Domain Therapeutics, an adMare portfolio company, announced first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors
"The successful initiation of this first-in-human study is a significant milestone for Domain. Our differentiated approach to tackling cancer with GPCR-based drug candidates is built on the premise that every cancer is unique. By treating patients based on their individual cancer signatures, we can deliver targeted, scientifically validated therapies," commented Dr. Pascal Neuville, CEO of Domain Therapeutics
Jazz Pharmaceuticals and Zymeworks, an adMare portfolio company, announced positive results from their phase 2 trial
Jazz Pharmaceuticals plc and Zymeworks Inc. announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma.
Lots of great news for adMare National Tx Accelerator
adMare BioInnovations launched the adMare Tx Accelerator to support the growth of promising early-stage therapeutics ventures across Canada - Read the press release
adMare partners with MaRS Discovery District to develop the MaRS-adMare Therapeutics Accelerator in Ontario - Read the press release
Quebec government invests nearly $7.2 million to support the activities of five Quebec incubators and accelerators, including adMare - Learn more (in French)
adMare is proud to be a partner in the five new multidisciplinary research hubs announced by the government of Canada.
By working alongside other partners in both research and industry, those hubs will develop an essential network that will enhance Canada's capabilities to respond quickly, effectively, and equitably to future pandemics.
In the Media
A look back at recent events
Celebrating the graduation of the first cohort of the Pilot Accelerator Program
On January 30th, we celebrated the journey of the 6 companies of the first cohort of the Pilot Accelerator Program with special guests, and we launched the adMare National Tx Accelerator.
adMare presented the Emerging Companies Forum at the BIOTECanada Whistler Investor Summit
Congratulations to the four companies who presented their project to the jury and attendees:
- Overture Therapeutics
- Find Therapeutics
- Immugenia Inc.
- Evolved Therapeutics
Industry Builder Series with Dr. Jeremy Duffield, CSO of Prime Medicine
adMare welcomed Dr. Jeremy Duffield, CSO of Prime Medicine, who presented recent development in precision gene editing technology called prime editing – a "search-and-replace" function.
The Global Leader Series recording featuring Dr. Melissa J. Moore is now available on the adMare Community
On February 22, Dr. Melissa Moore, the Chief Scientific Officer Emeritus of Moderna, related the fascinating story of the mRNA vaccine development. The replay is available on the adMare Community.
Effervescence, the Future of Life Sciences will be held in Montreal on May 3 and 4.
adMare is proud to present a discussion on scientific entrepreneurship with Axelys and our panelists:
- Mike (Przemyslaw) Sapieha, Founder and CSO at SemaThera
- Elie Haddad, Head, Pediatric Immunology and Rheumatology Division, Research Center of the Sainte-Justine University Hospital
- Philippe Crine, Founder, Enobia
- Christine Martens, Vice President, Sciences and Technologies, Axelys
- Mounia Azzi, Vice President, Corporate Development, adMare BioInnovations
- moderated by Isabelle Dubé, Journalist at La Presse.
Join us for this event!
adMare BioInnovations launches the BioInnovation Scientist (BIS) Program: Foundations and invites early-career science professionals to apply to be part of the inaugural cohort
The adMare Academy is proud to launch the BioInnovation Scientist (BIS) Program: Foundations. This online, cohort-based program will provide early-career scientists with fundamental knowledge in therapeutics development while simultaneously building their professional skills to succeed in the Canadian life sciences industry.
Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced three new biomanufacturing training facilities in British Columbia, Quebec, and Prince Edward Island
Canadian Alliance for Skills and Training in Life Sciences (CASTL) partners with the British Columbia Institute of Technology on a new biomanufacturing training facility. Read more
CASTL Announces Location for Quebec Biomanufacturing Training Facility. Read more
New BioAccelerator home to Canadian Alliance for Skills and Training in Life Sciences (CASTL) expanded training facility. Read more
A Final Word
Meet our scientists
Behind our Building Companies pillar is an in-house team of R&D scientists in chemistry, biology, and pharmacology. Located in both our Montreal and Vancouver innovations centers, these 42+ scientists are dedicated to validating research and helping progress drug discovery milestones.